Jci_page_head_homepage_01 Jci_page_head_homepage_02
Lian Zhang, Fangwen Rao, Kuixing Zhang, Srikrishna Khandrika, Madhusudan Das, Sucheta M. Vaingankar, Xuping Bao, Brinda K. Rana, Douglas W. Smith, Jennifer Wessel, Rany M. Salem, Juan L. Rodriguez-Flores, Sushil K. Mahata, Nicholas J. Schork, Michael G. Ziegler, Daniel T. O’Connor
Published in Volume 117, Issue 9
J Clin Invest. 2007; 117(9):2658–2671 doi:10.1172/JCI31093
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 8
Intermediate phenotypes.

In the “intermediate phenotype” schema, biochemical traits (such as NO production) are postulated to be determined earlier and more proximately by genotype (such as GCH1 3′-UTRs C+243T) than are physiological traits (such as heart rate variability and resting heart rate) and, ultimately, late-penetrance disease (such as cardiovascular disease, hypertension, or sudden death). Here the concept is illustrated by the findings at GCH1 in the current study: the GCH1 3′-UTRs variant C+243T initially alters NO production, subsequently influencing baroreceptor coupling and heart variability, later minimum resting heart rate, and finally basal BP in the population.